Navigation Links
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Date:8/19/2007

IRVING, Texas, Aug. 16 /PRNewswire-FirstCall/ Carrington Laboratories, Inc., a global provider of medical, nutraceutical, consumer and raw material products, announced today that it received a letter from The Nasdaq Stock Market informing the Company that Nasdaq has determined to delist the securities of the Company, and would suspend trading in the Company's shares effective as of the open of business on Thursday, August 16, 2007.

As previously announced, on May 23, 2007, Nasdaq informed the Company that it did not comply with Marketplace Rule 4310(c)(3), which requires the Company to have (i) a minimum of $2,500,000 in stockholders' equity; (ii) $35,000,000 market value of listed securities; or (iii) $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years. On review of a plan of compliance submitted by the Company, Nasdaq determined to deny the Company's request for continued listing. On June 19, 2007, Nasdaq notified the Company that its common stock would be delisted effective June 28, 2007, unless it requested a hearing. On June 25, 2007, the Company requested a hearing, which was scheduled for August 9, 2007.

The Company expects to be eligible for quotation on the OTC Bulletin Board through one or more market makers. The OTC Bulletin Board is a regulated quotation service that displays real-time quotes, last sale prices and volume information in over-the-counter securities. Additionally, the Company's common stock will trade in the "Pink Sheets," beginning on August 16, 2007. No assurance can be given that the Company's common stock will be quoted on the OTC Bulletin Board or that market makers currently making a market in the common stock will continue to make a market in the common stock. The Company will continue to make all required SEC filings and disclosures and will continue to communicate with shareholders as a public company.

About C
'/>"/>

SOURCE Carrington Laboratories, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)... , TUSTIN, Calif., Dec. 4 /PRNewswire-FirstCal...PPHM ) today announced that it will release its fi...ear 2009 on December 10, 2008 at 7:00 a.m. EST and...s the results at 11:30 a.m. EST on the same day. ...uss financial results for the second quarter ended...
(Date:12/4/2008)... CITY, Dec. 4 /PRNewswire-FirstCall/ - AEterna Zen...iopharmaceutical company focused on endocrine ther...nt and CEO, Juergen Engel, Ph.D., will take part i...ay With Newer And Better Agents" at the upcoming R...ednesday, December 10, 2008 at 4:30 pm (eastern ti...
(Date:12/4/2008)...L, WA, and VANCOUVER, Dec. 4 /PRNewswire-FirstCall... ) will participate on the ,Waging a Battle Agains...althcare Conference on Thursday, December 11 at 8:...ork. During the panel discussion, OncoGenex, Presi...ill provide a brief overview of the company,s onco...
(Date:12/3/2008)... and PHILADELPHIA, Dec. 3 /PRNewswire-FirstCall/ -...day that it is waiving a condition relating to a,... offer to purchase all of,the outstanding shares ...asdaq: GNLB ), for $1.30 per share in cash witho...es. , It is a condition to the completion o...
Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 3
...yless to describe his vision for GE. Specifically,...t-seven-signatures-before-buying-toilet-paper, bur...imbly into markets, execute quickly on decisions, ...o well to tear a note from Welchs playbook. Why? B...fashion. Its time economic developers craft polici...
...e first through the third, will be most interestin...Germany, France, Italy, Britain, Canada and Russia...es. Unfortunately, China is missing from the party...thats a huge mistake! , ,Usually these meetings a...oin hands and smile for the huge group of assemble...
...h Heling, co-founder, SecurePipe, Inc. SecurePip...de variety of industries including manufacturing, ...mer products and technology. Heling discusses inno...ey, and ecruiting a CEO. , , WTN: Please start b...Heling (JH): In 1996, I was doing back-end Unix s...
... Governor Doyle and organized by Forward Wisconsin...echnology industrys leading conference with goals ...capital, showcase the states research and universi... has a growing biotechnology community. According ...jectives in spite of limited conference participat...
Other Biology Technology:Are We Headed for a Global Economic Collapse? 2WTN Exclusive Interview with Josh Heling 2WTN Exclusive Interview with Josh Heling 3On site at BIO 2003 2On site at BIO 2003 3On site at BIO 2003 4On site at BIO 2003 5
(Date:12/3/2008)...uke University study suggests that evolution can b...ogs depend on an energy-efficient style of four-fo...ey, cats seem to have evolved a profoundly ineffic...ird in slow motion. , "It is usually assumed tha...aniel Schmitt, a Duke associate professor of evolu...
(Date:12/3/2008)...lem of children failing to take their medication f...tackled as part of a new university research proje...lists at The University of Nottingham and The Univ...f school children with asthma, diabetes, congenita...rriers that prevent them from taking medicines pre...
(Date:12/3/2008)...mber 3, 2008 Today, the International Society for...rofessional organization of stem cell researchers,...opment of safe and effective stem cell therapies f...the Guidelines for the Clinical Translation of Ste...ember issue of Cell Stem Cell , the official affi...
(Date:12/3/2008)...s that are high in protein and cereal grains produ...e calcium excretion and weaken bones, according to...rine Society,s Journal of Clinical Endocrinology ...asing the alkali content of the diet, with a pill ...s the opposite effect and strengthens skeletal hea...
Breaking Biology News(10 mins):Dogs chase efficiently, but cats skulk counterintuitively 2A spoonful of sugar? 2A spoonful of sugar? 3The International Society for Stem Cell Research releases new guidelines 2The International Society for Stem Cell Research releases new guidelines 3Calcium and vitamin D may not be the only protection against bone loss 2Intercim Launches Pertinence Suite Powered by Velocity 14544 1Intercim Launches Pertinence Suite Powered by Velocity 14544 2Intercim Launches Pertinence Suite Powered by Velocity 14544 3Intercim Launches Pertinence Suite Powered by Velocity 14544 4TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4043 1TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4043 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4043 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4043 4Peapod Offers First Ever Virtual Nutritionist 14537 1Peapod Offers First Ever Virtual Nutritionist 14537 2OPKO Health Announces Issuance of U S Patent Covering the Use and Administration of Certain Anti VEGF siRNAs Including Its Phase III Compound Bevasi 4042 1OPKO Health Announces Issuance of U S Patent Covering the Use and Administration of Certain Anti VEGF siRNAs Including Its Phase III Compound Bevasi 4042 2OPKO Health Announces Issuance of U S Patent Covering the Use and Administration of Certain Anti VEGF siRNAs Including Its Phase III Compound Bevasi 4042 3OPKO Health Announces Issuance of U S Patent Covering the Use and Administration of Certain Anti VEGF siRNAs Including Its Phase III Compound Bevasi 4042 4
...ersity of Wisconsin-Milwaukee, a Wisconsin biotech...found in jellyfish is neuro-protective and may be ..., Testing of aequorin has yielded promising result...ated in Madison. Researcher James Moyer, Jr., an a...n cells to the "lab" equivalent of a stroke, and m...
..."switch gene" in two groups of microscopic plankto...hether certain marine plankton convert a sulfur co...e it can affect the earth,s temperature, or remain... "This new gene offers a powerful tool to study th... sulfur exchange between the ocean and atmosphere,...
...s sack of chemicals and a living cell? It,s all in...biophysical chemist Steven Boxer. With colleagues ...d Lawrence Livermore National Laboratory, he has d...edented resolution-on the order of 100 nanometers,... smaller than entire cells. Understanding the chem...
... the National Cancer Institute, a Wake Forest Univ... to improve the effectiveness of a drug that he d..., Waldemar Debinski, M.D., Ph.D., pioneered a met...BM) with less damage to healthy cells. The drug is...inski is working on its fourth generation in the l...
Other Biology News:UWM brain research supports drug development from jellyfish protein 2Bacterial 'switch gene' regulates how oceans emit sulfur into atmosphere 2With record resolution and sensitivity, tool images how life organizes in a cell membrane 2With record resolution and sensitivity, tool images how life organizes in a cell membrane 3With record resolution and sensitivity, tool images how life organizes in a cell membrane 4With record resolution and sensitivity, tool images how life organizes in a cell membrane 5With record resolution and sensitivity, tool images how life organizes in a cell membrane 6Scientist works to improve treatment for brain tumors 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,518-2) or contact custom
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,517-4) or contact custom
Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /
Biology Products: